AI Market Mood: Stock Dashboard
XAIR
Fundamental
Company: Beyond Air Inc
Sector: Healthcare
Industry: Medical Devices
Country: USA
Exchange: NASD
Index: -
P/E: -
EPS (ttm): -7.53
Insider Own: 5.81%
Shs Outstand: 8.01M
Perf Week: -10.09%
Market Cap: 8.21M
Forward P/E: -
EPS next Y: -2.07
Insider Trans: 1.31%
Shs Float: 7.55M
Perf Month: -28.32%
Enterprise Value: 9.51M
PEG: -
EPS next Q: -0.69
Inst Own: 21.50%
Short Float: 4.88%
Perf Quarter: -57.64%
Income: -36.70M
P/S: 1.42
EPS this Y: 73.14%
Inst Trans: 2.47%
Short Ratio: 0.72
Perf Half Y: -71.46%
Sales: 5.80M
P/B: 0.64
EPS next Y Percentage: 44.15%
ROA: -87.40%
Short Interest: 0.37M
Perf YTD: -85.70%
Book/sh: 1.59
P/C: 0.76
EPS next 5Y: 74.09%
ROE: -179.63%
52W High: 11.20 -90.85%
Perf Year: -89.38%
Cash/sh: 1.36
P/FCF: -
EPS past 3/5Y: 25.75% 17.29%
ROIC: -152.16%
52W Low: 1.00 2.50%
Perf 3Y: -99.13%
Dividend Est.: -
EV/EBITDA: -
Sales past 3/5Y: - 21.66%
Gross Margin: -6.69%
Volatility W: 6.27%
Volatility M: 9.04%
Perf 5Y: -99.06%
Dividend TTM: -
EV/Sales: 1.64
EPS Y/Y TTM: 73.23%
Oper. Margin: -575.72%
ATR (14): 0.12
Perf 10Y: -
Dividend Ex-Date: -
Quick Ratio: 3.73
Sales Y/Y TTM: 147.74%
Profit Margin: -632.51%
RSI (14): 29.60
Recom: 1.50
Dividend Gr. 3/5Y: - -
Current Ratio: 4.24
EPS Q/Q: 77.97%
SMA20: -15.76%
Beta: 0.32
Target Price: 10.33
Payout: -
Debt/Eq: 0.93
Sales Q/Q: 127.82%
SMA50: -41.72%
Rel Volume: 0.15
Prev Close: 1.06
Employees: 61
LT Debt/Eq: 0.89
Earnings: Nov 10 AMC
SMA200: -67.93%
Avg Volume: 514.56K
Price: 1.02
IPO: Sep 23, 2016
Option/Short: No / Yes
EPS/Sales Surpr.: -61.64% -15.27%
Trades:
Volume: 56,318
Change: -3.30%
Technical:
Latest News:
New AI drug discovery powerhouse Xaira rises with $1B in funding - Fierce Biotech very bullish
XAIR
Summary: Xaira Therapeutics has emerged with $1 billion in committed funding and an impressive team led by prominent figures in the biotech industry, including Marc Tessier-Lavigne, Ph.D., and David Baker, Ph.D. The company aims to revolutionize drug discovery by combining machine learning, data generation, and therapeutic product development.
Full article2024-04-24T14:00:06Z